123 related articles for article (PubMed ID: 12389620)
1. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.
Au WY; Lie AK; Kwong YL; Shek TW; Hawkins BR; Lai KN; Tang SC; Lo CM; Fan ST; Liu CL; Chan GC; Chau EM; Chiu SW; Liang R
Leuk Lymphoma; 2002 Jul; 43(7):1403-7. PubMed ID: 12389620
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
[TBL] [Abstract][Full Text] [Related]
3. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F
Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Luo L; Zhang L; Cai B; Li H; Huang W; Jing Y; Zhu H; Zhao Y; Bo J; Wang Q; Han X; Yu L; Gao C
Ann Transplant; 2014 Jan; 19():6-12. PubMed ID: 24399278
[TBL] [Abstract][Full Text] [Related]
5. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma.
Lohrisch CA; Nevill TJ; Barnett MJ; Hogge DE; Connors JM; Keown PA; Gascoyne RD
Leuk Lymphoma; 2000 Sep; 39(1-2):195-201. PubMed ID: 10975399
[TBL] [Abstract][Full Text] [Related]
6. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
7. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
8. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia.
Buyck HC; Ball S; Junagade P; Marsh J; Chakrabarti S
Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495
[TBL] [Abstract][Full Text] [Related]
9. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
12. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.
Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K
Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484
[TBL] [Abstract][Full Text] [Related]
13. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
14. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
15. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
[TBL] [Abstract][Full Text] [Related]
16. Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.
Füreder A; Kropshofer G; Benesch M; Dworzak M; Greil S; Huber WD; Hubmann H; Lawitschka A; Mann G; Michel-Behnke I; Müller-Sacherer T; Pichler H; Simonitsch-Klupp I; Schwinger W; Szepfalusi Z; Crazzolara R; Attarbaschi A;
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1375. PubMed ID: 33755341
[TBL] [Abstract][Full Text] [Related]
17. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
Curtis RE; Travis LB; Rowlings PA; Socié G; Kingma DW; Banks PM; Jaffe ES; Sale GE; Horowitz MM; Witherspoon RP; Shriner DA; Weisdorf DJ; Kolb HJ; Sullivan KM; Sobocinski KA; Gale RP; Hoover RN; Fraumeni JF; Deeg HJ
Blood; 1999 Oct; 94(7):2208-16. PubMed ID: 10498590
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009.
Yoon SO; Yu E; Cho YM; Suh C; Kim KM; Han DJ; Lee SG; Huh J
Clin Transplant; 2012; 26(1):67-73. PubMed ID: 21269330
[TBL] [Abstract][Full Text] [Related]
20. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
